GPT and hyperuricemia: The most common adverse event in the MSC group was an increase in lactic acid dehydrogenase (13.85%), compared with 20% in the placebo group; a 10.77% elevation of serum alanine aminotransferase compared with 11.43% in the placebo group; a 9.23% increase in hypokalaemia compared with 2.86% in the placebo group; a 7.69% increase in aspartate aminotransferase compared with 11.43% in the placebo group; and a 7.69% increase in hyperuricemia compared with 8.75% in the placebo group.